Trial success for breast cancer test
This article was originally published in Clinica
Immunomedics' CEA-Scan test could improve the detection rate of breast cancers, even in women with non-palpable lesions, according to clinical trial results.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.